Adrian Haigh

Track

Insider profile

Currently holds positions in Fennec Pharmaceuticals Inc and Arch Biopartners Inc

Performance

Overall performance
1.7
Performance over holding periods
4.2
30 days 90 days 120 days
Average return -6% 8.2% 15.1%
Success rate 0% 68% 82%
Transactions
5 80% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
Performance for realised trades
4.4
Average return -10%
Success rate 73%
Average holding period 220
Transactions 28
Ranking by realised performance

Positions

Position Company Period
Independent Director Fennec Pharmaceuticals Inc April 28, 2014 -
Independent Director Arch Biopartners Inc Dec. 1, 2014 -
Interim Director Arch Biopartners Inc Aug. 21, 2014 - Dec. 1, 2014
Adrian Haigh's trades of Fennec Pharmaceuticals Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Proposed sale
Price
348.75
Quantity 86,729
Value US$2,758,598
Transaction date
Proposed sale
Price
482.35
Quantity 66,553
Value US$1,498,552
Transaction date
Proposed sale
Price
9.34
Quantity 22,222
Value US$207,458
Transaction date
Proposed sale
Price
9.62
Quantity 22,222
Value US$213,796
Transaction date
Proposed sale
Price
9.91
Quantity 22,222
Value US$220,220
Transaction date
Proposed sale
Price
10.28
Quantity 22,222
Value US$228,389
Transaction date
Proposed sale
Price
10.30
Quantity 22,222
Value US$228,793
NL Unilever PLC (ULVR)
Transaction date
Purchase
Price
37.63
Quantity 4,000
Value £150,500
Transaction date
Purchase
Price
2.90
Quantity 15,000
Value £43,470
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2024-09-05 2024-09-05
PrS Proposed sale
86,729
348.75
US$2,758,598 		86,729 348.75 US$2,758,598
2024-04-22 2024-04-22
PrS Proposed sale
66,553
482.35
US$1,498,552 		66,553 482.35 US$1,498,552
2024-04-22 2024-04-22
PlS Planned sale
68,865 +29.8%
284.49
US$4,212,209 		68,865 +29.8% 284.49 US$4,212,209
2024-04-22 2024-04-19
PlS Planned sale
22,222 -100.0%
9.34
US$207,442 		22,222 -100.0% 9.34 US$207,442
2024-04-19 2024-04-19
PrS Proposed sale
22,222
9.34
US$207,458 		22,222 9.34 US$207,458
2024-04-18 2024-04-18
PrS Proposed sale
22,222
9.62
US$213,796 		22,222 9.62 US$213,796
2024-04-18 2024-04-18
PlS Planned sale
22,222 -100.0%
9.62
US$213,776 		22,222 -100.0% 9.62 US$213,776
2024-04-18 2024-04-17
PlS Planned sale
22,222 -50.0%
9.91
US$220,220 		22,222 -50.0% 9.91 US$220,220
2024-04-17 2024-04-17
PrS Proposed sale
22,222
9.91
US$220,220 		22,222 9.91 US$220,220
2024-04-16 2024-04-16
PrS Proposed sale
22,222
10.28
US$228,389 		22,222 10.28 US$228,389
2024-04-16 2024-04-16
PlS Planned sale
22,222 -100.0%
10.28
US$228,389 		22,222 -100.0% 10.28 US$228,389
2024-04-16 2024-04-15
PlS Planned sale
22,222 -50.0%
10.30
US$228,793 		22,222 -50.0% 10.30 US$228,793
2024-04-15 2024-04-15
PrS Proposed sale
22,222
10.30
US$228,793 		22,222 10.30 US$228,793
2022-04-12 2022-04-12
B Purchase
14,125
3.56
£50,243 		14,125 3.56 £50,243
2022-02-11 2022-02-11
NL Unilever PLC (ULVR)
B Purchase
4,000
37.63
£150,500 		4,000 37.63 £150,500
2021-08-20 2021-08-20
B Purchase
15,000
2.90
£43,470 		15,000 2.90 £43,470
2019-05-13 2019-05-10
S Sale
13,701
61.43
£841,655 		13,701 61.43 £841,655
2018-10-01 2018-09-28
B Purchase
119
69.75
£8,300 		119 69.75 £8,300